USANA Health Sciences (USNA) Set to Announce Quarterly Earnings on Tuesday

USANA Health Sciences (NYSE:USNA) will be posting its quarterly earnings results after the market closes on Tuesday, July 23rd. Analysts expect USANA Health Sciences to post earnings of $0.65 per share for the quarter. USANA Health Sciences has set its FY 2024 guidance at 2.400-3.000 EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, April 30th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.69 by $0.17. The company had revenue of $227.80 million for the quarter, compared to analyst estimates of $223.27 million. USANA Health Sciences had a net margin of 6.88% and a return on equity of 12.80%. On average, analysts expect USANA Health Sciences to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

USANA Health Sciences Price Performance

USNA stock opened at $46.26 on Monday. USANA Health Sciences has a 12 month low of $41.45 and a 12 month high of $69.60. The company’s 50 day simple moving average is $46.40 and its 200-day simple moving average is $47.16. The firm has a market capitalization of $881.25 million, a PE ratio of 14.41, a P/E/G ratio of 1.39 and a beta of 0.90.

Insiders Place Their Bets

In other news, insider Paul A. Jones sold 2,714 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The shares were sold at an average price of $48.66, for a total value of $132,063.24. Following the completion of the transaction, the insider now owns 6,266 shares of the company’s stock, valued at $304,903.56. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Daniel A. Macuga sold 3,791 shares of the company’s stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $47.14, for a total transaction of $178,707.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Jones sold 2,714 shares of the firm’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $48.66, for a total transaction of $132,063.24. Following the completion of the sale, the insider now directly owns 6,266 shares in the company, valued at $304,903.56. The disclosure for this sale can be found here. Insiders have sold 31,591 shares of company stock valued at $1,458,098 in the last ninety days. Insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Separately, DA Davidson cut their price target on USANA Health Sciences from $48.00 to $46.00 and set a “neutral” rating for the company in a report on Tuesday, May 7th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.